HOME >> BIOLOGY >> NEWS
A single sugar found responsible for an antibody's ability to treat inflammation

For years, researchers have struggled to understand how IVIG worked. It's ability to treat autoimmune diseases seemed to bean apparent contradiction.

Intravenous immunoglobulin (IVIG) is a complex mixture of IgG antibodies made from human plasma that contains the pooled antibodies from thousands of people, and is only FDA-approved to treat a few assorted conditions; nonetheless, practitioners have used it off-label with varied success in patients with lupus, arthritis and asthma, among other autoimmune disorders. In the body, the antibodies in plasma act as part of the immune response to identify and deactivate foreign invaders. When they begin attacking the body's own cells, the same protective immunoglobulins (known as IgG antibodies) can cause autoimmune disorders like lupus, arthritis and asthma. And yet, when IVIG is infused into people with those exact autoimmune conditions, it calms inflammation rather than causes it.

Jeffery Ravetch, Theresa and Eugene M. Lang Professor and head of Rockefeller's Laboratory of Molecular Genetics and Immunology, was struck by this inconsistency. "If IgG triggers autoimmune disease, how could it be pathogenic and therapeutic?" he asked. "We call it the IgG paradox." Six years ago he started an investigation into exactly how IVIG worked, and what he's discovered could one day lead to a whole new class of therapeutics. In a paper published today in the journal Science, Ravetch and his colleagues, Falk Nimmerjahn and Yoshi Kaneko explain what makes IVIG effective: A small fraction of the IgG antibodies in the IVIG solution carry a sugar called sialic acid that is required for its protective ability.

IgG antibodies bind to and activate specific immune cells, with different forms or "subclasses" binding to specific receptors (called Fc receptors) on the immune cell's surface. Antibody subclasses have different abilities to induce inflammation in the body by virtue of their selective ability to engage ei
'"/>

Contact: Kristine Kelly
kkelly@rockefeller.edu
212-327-7146
Rockefeller University
3-Aug-2006


Page: 1 2 3

Related biology news :

1. New research proves single origin of humans in Africa
2. 5 OHSU faculty members singled out for honors
3. TU Delft tracks the influence of a cancer inhibitor on a single DNA molecule
4. Caribbean frog populations started with single, ancient voyage on South American raft
5. Caribbean frogs started with a single, ancient voyage on a raft from South America
6. The social life of honeybees coordinated by a single gene
7. Penn researchers replace organ in adult mice using single-parent stem cells
8. Scripps research study reveals structural dynamics of single prion molecules
9. New nanotechnology able to examine single molecules, aiding in determining gene expression
10. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
11. Scientists discuss new frontiers in single-molecule research at American Chemical Society

Post Your Comments:
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
(Date:10/15/2014)... linked increased resistance to bacterial pneumonia in female mice ... estrogen. , Females are naturally more resistant to respiratory ... has shown that increased resistance to bacterial pneumonia in ... synthase 3 (NOS3). They also show that this enzyme ... sex hormone estrogen. , The team, lead by Professor ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to ... the development of skin cancers by turning on an ... skin cells. , Previously considered protective, SIRT6 is part ... help regulate genomic stability and prevent some of the ... damage, which can lead to cancer. This study, in ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/25/2014)... October 24, 2014 Today, Nerium International, ... the winners of its “Reflect Your Youth” contest, an ... only seen a difference in their skin since using ... new outlook on life as a result of their ... as an effort by Nerium International to inspire conversations ...
(Date:10/25/2014)... , October 24, 2014 ... clinical-stage pharmaceutical company focused on the development of oral ... Nadav Kidron will present at FireRock Capital,s ... Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ... New York City , ...
(Date:10/25/2014)... 2014 Research and Markets has ... Product , Research Area & by End User - ... In this report, the global epigenetics ... areas, and end users. The product segments of the ... & consumables, kits, and reagents. The subsegments of the ...
(Date:10/22/2014)... DUBLIN and BOSTON , ... ACT ), a leading global specialty pharmaceutical company, and ... been granted an exclusive option to acquire Rhythm,s wholly ... (RM-131), a peptide ghrelin agonist, for the treatment of ... Rhythm has completed a successful Phase 2 trial ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
Cached News: